CKS1B amplification is an independent adverse prognostic factor for patients with multiple myeloma who underwent an autologous hematopoietic stem cell transplantation

Progression-free survival after autologous hematopoietic stem cell transplantation for multiple myeloma patients receiving an autologous hematopoietic stem cell transplantation with CKS1B amplification is 15 months

Even with a proteasome inhibitor or an immunomodulatory drug-based induction and the use of post-transplantation maintenance therapy, patients with CKS1B amplification have poor outcome